Loading...
DOCUMENTS
20
NOTICES
33
MOTS CLES
Eradication
IL23
Inhibitor
Gènes
Colectomy
COLON-CANCER
Fecal microbiota
Monitoring
IBD
Endoscopic treatment
CARCINOGENESIS
Clinical guidelines
Maintenance therapy
Resistance
HIV
Venous thromboembolism
Cell adhesion
Patients experience
Intestinal crypts
Méthylation
RISK
Disability
Rituximab plus chlorambucil
Crohn's disease
Thérapie ciblée
Microbiote
Acceptability
Biologics
Therapeutics
Disease Progression
Drug
Inflammatory Bowel Diseases
Survival
Inclusion
Neoadjuvant chemotherapy
Methylation
Epigénétiques
T1118 translocation
Anti-TNF
Parvimonas micra
Gene expression
PCR
Alkylating agents
Safety
Crohn’s disease
Dysbiose
Cost effectiveness
Patient-reported outcome
Heart disease risk factors
Colon
Over 80s
18 FDG-PET/CT
Original Article Clinical
Immune cells
Stricture
Tuberculosis
MICROBIOTA
Bacteria
Contraindication
IL12
Biomarker
Colonic epithelial primary cells
Microbiota
Tailored therapy
Anti-TNF agents
Colorectal cancer
Bactéries
Colon cancer
Helicobacter pylori
Immunosuppressant
Ulcerative colitis
Algorithm
Résistance
Upper gastrointestinal tract
Disease progression
MARKER
Surgery
Colorectal cancer Colibactin and lipids
Clinical trial
Kidney diseases
Screening
Small molecules
Dysbiosis
Rituximab
Genes
Effectiveness
DNA methylation
Gene methylation
Inflammatory bowel diseases
Primary sclerosing cholangitis
Epigenetics
Consensus
DNA METHYLATION
Cancer
MORTALITY
Ustekinumab
MALT
Eligibility
Inflammatory bowel disease
Vedolizumab
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|